Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Mina, Syeda A.; Muhsen, Ibrahim N.; Burns, Ethan A.; Sarfraz, Humaira; Pingali, Sai Ravi; Xu, Jiaqiong; Hashmi, Shahrukh K.

Mina, Syeda A.; Muhsen, Ibrahim N.; Burns, Ethan A.; Sarfraz, Humaira; Pingali, Sai Ravi; Xu, Jiaqiong; Hashmi, Shahrukh K..

Afiliação

Mina SA; Mayo Clinic, Department of Medicine, Rochester, USA
Muhsen IN; Houston Methodist Hospital, Department of Medicine, Houston, USA
Burns EA; Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, USA
Sarfraz H; Houston Methodist Hospital, Department of Medicine, Houston, USA
Pingali SR; Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, USA
Xu J; Center for Outcomes Research, Houston Methodist Research Institute, Houston, USA
Hashmi SK; Mayo Clinic, Department of Medicine, Rochester, USA

Turk J Haematol ; 38(3): 218-221, 2021 08 25.

Article em En | MEDLINE | ID: mdl-34190655

Assuntos

Doenças do Sistema Nervoso Periférico; Inibidores de Proteassoma; Bortezomib/efeitos adversos; Humanos; Marketing; Doenças do Sistema Nervoso Periférico/induzido quimicamente; Doenças do Sistema Nervoso Periférico/epidemiologia; Inibidores de Proteassoma/efeitos adversos; Estados Unidos/epidemiologia; United States Food and Drug Administration

Palavras-chave

Multiple myeloma; Proteasome inhibitors; Peripheral neuropathy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Periférico / Inibidores de Proteassoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google